| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
HYDERABAD, India—Dr. Reddy's Laboratories Ltd.announced Oct. 22 that is has reached conditional agreement with Leiden, theNetherlands-based OctoPlus on a public offer for all issued and outstandingordinary shares in the capital of OctoPlus at an offer price totaling roughly$36 million.
 
 
This price represents a premium of 30 percent overOctoPlus' most recent closing price at the time of the announcement and apremium of 36 percent, 28 percent and 14 percent, respectively, over OctoPlus'average closing price for the past three, six and 12 months.
 
 
The executive board and the supervisory board ofOctoPlus are said to both fully support the offer, and are recommending thatOctoPlus' shareholders sell their stock to Dr. Reddy's.
 
 
G.V. Prasad, CEO of Dr. Reddy's, says his companylooks forward to having a research and development base in the Leiden area andadds, "the acquisition gives us the ability to strengthen our technologicalcapabilities in the areas of drug delivery."
 
 
With the recent "value erosion" of Locteron, ahepatitis C drug OctoPlus was co-developing with Pittsboro, N.C.-based BiolexTherapeutics—but which never gained financing to push is to Phase III clinicaltesting status—OctoPlus' leaders felt that they needed to review a number ofalternative strategies for our company, finally concluding, according toOctoPlus, that the intended offer by Dr. Reddy's best serves the interest of thecompany's key stakeholders, "including our employees and shareholders."
 
 
Dr. Reddy's maintains that OctoPlus' developmentand manufacturing platform perfectly fits with its own marketing abilities,with a news release about the deal noting that "Dr. Reddy's is keen to furtherexpand into the fast growing fee-for-service business" and, to that extent, Dr.Reddy's "will retain OctoPlus as a specialist standalone entity to developspecialty generics for Dr. Reddy's. OctoPlus will become Dr. Reddy's center ofexcellence for complex injectables with retention of our highly skilled anddedicated professionals in our Leiden facility."
  
 
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue